vimian™

Q4 2025

Year-end report
January - December

Year-end report January - December 2025

Solid finish to 2025

Fourth quarter

- Revenue increased by 4 per cent to EUR 109.0m (104.9) with organic growth of 6 per cent. Acquisitions contributed with 3 per cent and negative impact from currency movements of -4 per cent.
- Operating profit (EBIT) of EUR 19.2m (12.5)
- EBITA of EUR 25.4m (18.3), including items affecting comparability of EUR -0.7m (-6.2). Adjusted EBITA increased 6 per cent to EUR 26.1m (24.6) corresponding to a margin of 24.0 per cent (23.4)
- Profit for the period of EUR 12.2m (12.5) and earnings per share before and after dilution EUR 0.02 (0.02)
- Cash flow from operating activities of EUR 55.7m (24.4)

Full year

- Revenue increased by 13 per cent to EUR 425.0m (374.8) with organic growth of 6 per cent. Acquisitions contributed with 10 per cent and negative impact from currency movements of -2 per cent.
- Operating profit (EBIT) of EUR 66.8m (49.2)
- EBITA of EUR 90.7m (71.6), including items affecting comparability of EUR -14.7m (-23.7). Adjusted EBITA increased 11 per cent to EUR 105.3m (95.2) corresponding to a margin of 24.8 per cent (25.4)
- Profit for the period of EUR 32.3m (19.3) and earnings per share before and after dilution EUR 0.06 (0.04)
- Cash flow from operating activities of EUR 105.7m (58.1)
- The Board's proposal to the annual general meeting in April 2026, is to not distribute a dividend for 2025

Significant events during the fourth quarter

- On 24 November, Alireza Tajbakhsh was appointed Group CEO.
- In November and December, share issues of class D shares, class E1 shares, class E2 shares, and class E3 shares within the framework of Vimian's incentive program LTIP 2025/2028 were carried out. The number of shares increased by a total of 2,359,260 shares.

Significant events after the fourth quarter

- On 12 January, Vimian announced that Magnus Kjellberg, Head of Specialty Pharma, decided to step down during spring and that Carl-Johan Zetterberg Boudrie is appointed interim Head of Specialty Pharma in addition to his position as CFO.

Financial key ratios

EURm, unless otherwise stated	Oct-Dec 2025	Oct-Dec 2024	Δ%	Jan-Dec 2025	Jan-Dec 2024	Δ%
Revenue	109.0	104.9	*4%*	425.0	374.8	*13%*
Organic revenue growth (%)[1]	6%	15%		6%	9%	
EBITA	25.4	18.3	*39%*	90.7	71.6	*27%*
EBITA margin (%)	23.4%	17.5%	*5.9 pp*	21.3%	19.1%	*2.2 pp*
Adjusted EBITA[1]	26.1	24.6	*6%*	105.3	95.2	*11%*
Adjusted EBITA margin (%)[1]	24.0%	23.4%	*0.6 pp*	24.8%	25.4%	*-0.6 pp*
Operating profit (EBIT)	19.2	12.5	*54%*	66.8	49.2	*36%*
Profit for the period	12.2	12.5		32.3	19.3	*67%*
Items affecting comparability[2]	-0.7	-6.2		-14.7	-23.7	
Earnings per share before dilution (EUR)	0.02	0.02		0.06	0.04	
Earnings per share after dilution (EUR)	0.02	0.02		0.06	0.04	
Cash flow from operating activities	55.7	24.4	*128%*	105.7	58.1	*82%*

[1] Refer to the section on Alternative performance measures for more information.
[2] Refer to Note 3 and the section on Items affecting comparability for more information.

Message from our CEO

Solid finish to 2025

Vimian delivered a solid finish to 2025, with fourth quarter revenues of EUR 109 million and organic growth of 6 per cent. Adjusted EBITA grew 6 per cent in the quarter to EUR 26.1 million at a margin of 24.0 (23.4) per cent. At the end of the quarter, we signed the acquisition of I-Vet, one of the leading providers of companion animal diagnostics in Italy, with revenues of around EUR 5.6 million.

The quarter closed out 2025 where our two-pronged strategy of organic and acquisition driven growth delivered 13 per cent revenue growth to EUR 425 million and adjusted EBITA growth of 11 per cent to EUR 105.3 million. We delivered a strong operational cash generation of EUR 105.7 million, including EUR 28.7 million in payments following the positive judgment in the US indemnification dispute.

In 2025, we continued to deliver on our strategy of driving sustainable organic growth by educating 65,000 veterinary professionals and launching 94 new products. We welcomed five new businesses during the year, adding EUR 17.5 million in revenues, and we expanded our M&A pipeline. In March, we changed listing venue to Nasdaq Stockholm Main Market, and during the year we improved our ESG ratings with both MSCI (AA) and Sustainalytics (Low Risk).

Specialty Pharma – continued strong momentum
Specialty Pharma achieved 6 per cent organic growth for the fourth quarter with strong contribution from the dermatology portfolio. Growth in the quarter continued to be driven by innovation within a strong brand portfolio, our cross-sales activities and veterinary education.

For the full year, Specialty Pharma grew revenues by 6 per cent to EUR 182.4 million and adjusted EBITA by 10 per cent to EUR 53.9 million. The full year margin increased to 29.6 (28.6) per cent, primarily driven by operating leverage.

MedTech – strong growth in dental
MedTech delivered 4 per cent organic growth in the fourth quarter, with continued strong growth in our dental business, and solid performance in orthopedics in Europe and Asia-Pacific. Our efforts to improve performance in US orthopedics, which I have been running as interim since summer, continued in the quarter and we are seeing early results. During the quarter we completed a reorganisation, built out our field sales organisation and streamlined our product portfolio. We are still in a transition phase during the first months of 2026, and I am confident that our measures will generate results over time and that the long-term growth prospects for US orthopedics remain highly attractive.

For the full year, MedTech grew revenues by 25 per cent to EUR 155.5 million, where the successful acquisitions from the past 18 months of four companies within dentistry contributed 30 per cent. Full year adjusted EBITA grew 15 per cent to EUR 39.6 million. The full year margin decreased to 25.5 (27.7) per cent, driven by the consolidation of our dental business iM3 that operates at a lower margin, and lower sales in orthopedics.

Veterinary Services – investing in new markets
Veterinary Services delivered 10 per cent organic growth in the quarter, and as previously communicated we are investing in new geographies and services. In October, we completed the acquisition of a services platform in Belgium with 300 member clinics and reached 10,900 member clinics globally by the end of the year.

For the full year, Veterinary Services increased revenues by 11 per cent to EUR 64.3 million and adjusted EBITA grew 9 per cent to EUR 18.4 million. Full year margins decreased somewhat to 28.6 (29.2) per cent as we continued our investments to drive long-term growth.

Diagnostics – strengthening companion animal diagnostics
Diagnostics reported 5 per cent organic growth in the quarter. For the full year, Diagnostics grew revenues by 9 per cent to EUR 22.9 million while adjusted EBITA declined by -3 per cent to EUR 2.2 million. The full year margin decreased to 9.5 (10.8) per cent driven by our strategic investments to strengthen the companion animal diagnostics offering.

Delivering on our strategy
Vimian is a company with leading expertise and strong positions in fast-growing animal health niches with clear unmet medical needs. During four years as Head of Veterinary Services, where the business developed from a Northern European purchasing organisation into a global service platform with over 10,000 member clinics, I have personally experienced Vimian's ability to attract talent and entrepreneurs and take something relatively small with potential and build it on a global scale to a market leader.

With a deep knowledge of the sector, our customers, the business and the organisation, I look forward to continuing to lead the work across our four segments by strengthening and accelerating what works well and addressing what can be done better. The recruitments for a Head of MedTech and Head of Specialty Pharma are ongoing at full speed, and in the interim, we have secured a strong transition plan with CFO Carl-Johan Zetterberg as interim Head of Specialty Pharma, while I continue to manage the MedTech segment on an interim basis.

We see significant potential in our existing product and service portfolio and in our ability to continue to grow the Group. My operational focus will be on implementation and execution of our two-pronged strategy and on continuing to build strong teams with clear goals and responsibilities. With an active and selective acquisition agenda, we will continue to attract and welcome entrepreneurs and companies with high ambitions and together drive innovation to improve animal health.

Alireza Tajbakhsh
CEO of Vimian Group AB (publ)

Group performance

Fourth quarter 2025

Revenue
Revenue increased by 4 per cent to EUR 109.0m (104.9). Organic revenue growth was 6 per cent driven by Specialty Pharma and Veterinary Services with 6 per cent and 10 per cent organic growth respectively. MedTech organic growth was 4 per cent in a continued soft US surgery market. Diagnostics delivered organic growth of 5 per cent.

Acquisitions contributed with 3 per cent and negative impact of -4 per cent from currency movements.

Operating profit
Operating profit (EBIT) amounted to EUR 19.2m (12.5) at a margin of 17.7 per cent (12.0). This includes items affecting comparability of EUR -0.7m (-6.2).

The majority of items affecting comparability relates to MedTech with EUR -1.6m in restructuring costs and 2.7m relating to payments net of litigation costs in the US indemnification dispute. Acquisition related costs amounted to EUR 1.1m in total for the Group. For further information on items affecting comparability, refer to Note 3.

EBITA
EBITA increased by 39 per cent to EUR 25.4m (18.3) at a margin of 23.4 per cent (17.5).

Adjusted EBITA
Adjusted EBITA increased by 6 per cent to EUR 26.1m (24.6) at a margin of 24.0 per cent (23.4). The margin increase is primarily an effect of consolidation of bolt-on acquisitions within MedTech dentistry in 2025.

Financial items
Net financial items amounted to EUR -7.5m (2.5). This consists of four main parts: (1) financing expenses of EUR -4.1m with an average interest rate of 4.5 per cent during the quarter; (2) a quarterly discounting impact of EUR -1.6m and negative impact of EUR -3.1m from probability adjustments related to contingent considerations; (3) negative result of EUR -0.7m from liquidation and divestment of subsidiaries and (4) a positive impact of EUR 2.2m from exchange rate effects on the revaluation of debt.

Tax
Income tax expense for the quarter was EUR 0.8m (-2.4) at an effective positive tax rate of 7 per cent. In the fourth quarter the tax expense as percentage of pre-tax profit was positively affected by recognition of deferred tax on tax losses carried forward at year-end, amounting to EUR 3.7m. The effective tax rate was inflated by non-deductible expenses, mainly probability adjustments of contingent liabilities.

Profit for the period
Profit for the period amounted to EUR 12.2m (12.5), positively impacted by EUR 2.2m from exchange rates included in financial items and negatively by EUR -3.1m from probability adjustment on contingent liabilities. Earnings per share before and after dilution amounted to EUR 0.02 (0.02).

Quarterly revenue



Quarterly adjusted EBITA



January to December 2025

Revenue
Revenue increased by 13 per cent to EUR 425.0m (374.8). Organic revenue growth was 6 per cent with Specialty Pharma 8 per cent and Veterinary Services 11 per cent. MedTech total revenue growth of 25 per cent including acquisitions, organic growth was -1 per cent in a soft US surgery market. Diagnostics delivered organic growth of 10 per cent.

Acquisitions contributed to a growth of 10 per cent and there was a negative impact of -2 per cent from currency movements.

Operating profit
Operating profit amounted to EUR 66.8m (49.2) at a margin of 15.7 per cent (13.1). This includes items affecting comparability of EUR -14.7m (-23.7).

EBITA
EBITA of EUR 90.7m (71.6) at a margin of 21.3 per cent (19.1).

Adjusted EBITA
Adjusted EBITA increased by 11 per cent to EUR 105.3m (95.2) and the adjusted EBITA margin declined to 24.8 per cent (25.4). The margin decline was primarily driven by the MedTech segment, with consolidation of the dental business iM3 that has different financial profile, and lower sales in US orthopedics.

Financial items
Net financial items amounted to EUR -20.6m (-20.3). This consists of four main parts: (1) financing expense of EUR -15.4m with an average interest rate of 4.7 per cent, partly offset by EUR 1.2m interest income; (2) year-to-date discounting impact of EUR -5.3m, and impact from probability adjustments of EUR -4.5m related to contingent considerations; (3) negative result of EUR -0.7m from liquidation and divestment of subsidiaries and (4) a positive impact of EUR 4.1m from exchange-rate effects on revaluation of debt.

Tax
Income tax expense of EUR -13.5m (-9.5) at an effective tax rate of 29 per cent (33). The tax expense as percentage of pre-tax profit is inflated by additional tax paid for reassessment of prior year taxes, and non-deductible expenses, mainly non-realised currency impact recognised in the financial items and probability adjustments of contingent liabilities.

Profit for the period
Profit for the period January to December amounted to EUR 32.3m (19.3). Earnings per share before and after dilution amounted to EUR 0.06 (0.04).

Cash flow
Cash flow from operating activities reached EUR 105.7m (58.1) including payment from US indemnification dispute of EUR 28.7m.

Cash flow from investing activities of EUR -112.8m (-76.0) primarily consisting of acquisitions as well as earn-out payments. Cash flow from financing activities amounts to EUR -1.2m (44.8) which includes the refinancing of existing facilities.

Net working capital
Net working capital amounted to EUR 96.6m (100.1) per the end of December at 23 (27) per cent of revenue, a decrease from EUR 102.2m at the end of September 2025 (24 per cent of revenue).

Compared to end of September 2025, net working capital decreased by EUR 5.6m mainly related to lower current receivables and increase in trade payables.

Capital expenditure
Capital expenditure amounted to EUR -15.1m (-14.2). This is split between EUR -6.0m investments in intangible assets (internal R&D, software development and R&D partnerships) and EUR -9.1m investments in property, plant and equipment (the larger investments include new educational equipment in MedTech and other equipment in Specialty Pharma as well as build out of clinic capacity in Veterinary Services).

The capex of EUR -15.1m accounts for 3.6 per cent of sales, compared to 3.8 per cent for the same period in the previous year. The lower capex as a percentage of sales is primarily due to lower investments in intangible assets and capitalized R&D. Investments in property, plant and equipment have increased slightly year on year.

Net debt and cash and cash equivalents
At the end of the period, net debt amounted to EUR 245.4m (222.0), down from EUR 253.5m per 30 September 2025. Cash and cash equivalents amounted to EUR 55.0m (64.8) an increase compared to EUR 51.3m at the end of September. External lending of EUR 223.3m (215.9).

Per 31 December, net debt in relation to pro-forma adjusted EBITDA over the past 12-month period was 2.0x, a decrease from 2.1x compared to 30 September 2025.

Central Costs
Central costs amounted to EUR -8.8m (-7.4). Central costs include EUR -1.1m expenses related to the 2024 and 2025 long term incentive programmes (employee stock options and investment shares). These are non-cash IFRS expenses that will recur at for the duration of the three-year programs.

Segment performance

Fourth quarter and January - December 2025

Vimian operates through four reporting segments: Specialty Pharma, MedTech, Veterinary Services and Diagnostics

Revenue

EURm	Oct-Dec 2025	Oct-Dec 2024	Δ	Jan-Dec 2025	Jan-Dec 2024	Δ
Specialty Pharma	46.0	45.2	*2%*	182.4	172.0	*6%*
MedTech	40.1	38.4	*4%*	155.5	123.9	*25%*
Veterinary Services	16.8	15.4	*9%*	64.3	58.0	*11%*
Diagnostics	6.1	5.9	*4%*	22.9	20.9	*9%*
Group	**109.0**	**104.9**	***4%***	**425.0**	**374.8**	***13%***

Adjusted EBITA

EURm	Oct-Dec 2025	Oct-Dec 2024	Δ	Jan-Dec 2025	Jan-Dec 2024	Δ
Specialty Pharma	13.8	13.3	*4%*	53.9	49.2	*10%*
MedTech	9.9	8.0	*23%*	39.6	34.3	*15%*
Veterinary Services	4.5	5.0	*-11%*	18.4	16.9	*9%*
Diagnostics	0.6	0.6	*-8%*	2.2	2.3	*-3%*
Group Functions	-2.6	-2.4	*8%*	-8.8	-7.4	*18%*
Group	**26.1**	**24.6**	***6%***	**105.3**	**95.2**	***11%***

Revenue per segment, Q4 2025



Adjusted EBITA per segment, Q4 2025[1]



[1] Adjusted EBITA before central costs.

Segment – Specialty Pharma

EURm	Oct-Dec 2025	Oct-Dec 2024	Δ	Jan-Dec 2025	Jan-Dec 2024	Δ
Revenue	46.0	45.2	*2%*	182.4	172.0	*6%*
Organic revenue growth (%)	6%	22%	*-16 pp*	8%	15%	*-7 pp*
EBITA	13.7	10.4	*31%*	53.3	42.2	*26%*
EBITA margin (%)	29.7%	23.1%	*6.6 pp*	29.2%	24.5%	*4.7 pp*
Adjusted EBITA	13.8	13.3	*4%*	53.9	49.2	*10%*
Adjusted EBITA margin (%)	30.0%	29.4%	*0.6 pp*	29.6%	28.6%	*1.0 pp*

Revenue
Revenue in the fourth quarter grew 2 per cent to EUR 46.0 million (45.2). Organic growth was 6 per cent, with no contribution from acquisitions and -4 per cent negative impact from currency movements.

Continued organic growth across all therapeutic areas, with strong contribution from Dermatology in the quarter. Excluding the positive impact from a national sales campaign in US in the fourth quarter of 2024, the underlying organic growth was 12 per cent in the fourth quarter.

During the fourth quarter 12 new products were launched.

Net revenue during January to December grew 6 per cent to EUR 182.4 million (172.0). Organic growth of 8 per cent, with no contribution from acquisitions and -2 per cent negative impact from currency movements.

The segment's cross-selling and internationalisation initiatives accounted for approximately one third of the organic growth in 2025.

Adjusted EBITA
Adjusted EBITA for the fourth quarter increased by 4 per cent to EUR 13.8 million (13.3) at a margin of 30.0 per cent (29.4). The year-over-year margin improvement was driven by revenue growth and improved gross margin.

Adjusted EBITA for the period January to December increased by 10 per cent to EUR 53.9 million (49.2) at a margin of 29.6 per cent (28.6).

Quarterly revenue Specialty Pharma



Quarterly adjusted EBITA Specialty Pharma



Segment – MedTech

EURm	Oct-Dec 2025	Oct-Dec 2024	Δ	Jan-Dec 2025	Jan-Dec 2024	Δ
Revenue	40.1	38.4	*4%*	155.5	123.9	*25%*
Organic revenue growth (%)	4%	4%	*-0 pp*	- 1%	0%	*-1 pp*
EBITA	10.4	5.6	*86%*	29.9	20.0	*49%*
EBITA margin (%)	25.9%	14.6%	*11.3 pp*	19.2%	16.2%	*3.1 pp*
Adjusted EBITA	9.9	8.0	*23%*	39.6	34.3	*15%*
Adjusted EBITA margin (%)	24.6%	20.9%	*3.7 pp*	25.5%	27.7%	*-2.2 pp*

Revenue

Revenue in the fourth quarter increased 4 per cent to EUR 40.1 million (38.4). Organic growth of 4 per cent, with 6 per cent from acquisitions in veterinary dental and -6 per cent negative impact from currency movements.

Organic growth was driven by the dental business and orthopedics in Europe and Asia-Pacific. Orthopedic sales in North America continued to improve sequentially while year-over-year organic growth was slightly negative in a soft US surgery market.

Revenue during January to December grew 25 per cent to EUR 155.5 million (123.9). The decline in organic growth of -1 per cent was driven by orthopedics in the US. Acquisitions within the dental sub-segment contributed with 30 per cent growth. Negative impact from currency movements of -3 per cent.

Adjusted EBITA

Adjusted EBITA in the fourth quarter increased to EUR 9.9 million (8.0) at a margin of 24.6 per cent (20.9). The margin improvement was driven by the consolidation of bolt-on acquisitions within dentistry in 2025.

Adjusted EBITA for the period January to December increased by 15 per cent to EUR 39.6 million (34.3) at a margin of 25.5 per cent (27.7). The margin decline was driven by the consolidation of the dental business iM3 and lower sales in US orthopedics.

Quarterly revenue MedTech



Quarterly adjusted EBITA MedTech



Segment – Veterinary Services

EURm	Oct-Dec 2025	Oct-Dec 2024	Δ	Jan-Dec 2025	Jan-Dec 2024	Δ
Revenue	16.8	15.4	*9%*	64.3	58.0	*11%*
Organic revenue growth (%)	10%	16%	*-6 pp*	11%	16%	*-5 pp*
EBITA	4.2	4.5	*-6%*	18.0	15.8	*14%*
EBITA margin (%)	25.3%	29.4%	*-4.1 pp*	28.1%	27.3%	*0.8 pp*
Adjusted EBITA	4.5	5.0	*-11%*	18.4	16.9	*9%*
Adjusted EBITA margin (%)	26.6%	32.5%	*-5.8 pp*	28.6%	29.2%	*-0.6 pp*

Revenue
Revenue for the fourth quarter grew 9 per cent to EUR 16.8 million (15.4). Organic growth of 10 per cent, 1 per cent contribution from acquisitions and -1 per cent from currency movements.

The member base continued to increase reaching 10,900 members by the end of the year. The combination of continued growth in new members, development of the service offering and conversion of existing members to higher membership tiers continued to support the double-digit organic growth.

Co-owned clinics accounted for approximately a third of segment revenue and delivered high single-digit growth in the quarter.

Revenue for the period January to December grew 11 per cent to EUR 64.3 million (58.0). Organic growth of 11 per cent, 0 per cent contribution from acquisitions and -1 per cent from currency movements.

Adjusted EBITA
Adjusted EBITA for the fourth quarter decreased 11 per cent to EUR 4.5 million (5.0) at a margin of 26.6 per cent (32.5).

The year-over-year margin was impacted by unfavorable mix effects and investments in new markets and services.

Adjusted EBITA for the period January to December increased by 9 per cent to EUR 18.4 million (16.9) at a margin of 28.6 per cent (29.2).

Quarterly revenue Veterinary Services



Quarterly adjusted EBITA Veterinary Services



Segment – Diagnostics

EURm	Oct-Dec 2025	Oct-Dec 2024	Δ	Jan-Dec 2025	Jan-Dec 2024	Δ
Revenue	6.1	5.9	*4%*	22.9	20.9	*9%*
Organic revenue growth (%)	5%	12%	*-7 pp*	10%	- 2%	*13 pp*
EBITA	0.0	0.6	*-96%*	1.4	2.2	*-34%*
EBITA margin (%)	0.4%	9.6%	*-9.2 pp*	6.3%	10.4%	*-4.1 pp*
Adjusted EBITA	0.6	0.6	*-8%*	2.2	2.3	*-3%*
Adjusted EBITA margin (%)	9.2%	10.4%	*-1.2 pp*	9.5%	10.8%	*-1.2 pp*

Revenue

Revenue increased by 4 per cent to EUR 6.1 million (5.9). Organic growth of 5 per cent, with no contribution from acquisitions and -1 per cent negative impact from currency movements.

Organic growth was supported by disease outbreaks.

Revenue for the period January to December increased 9 per cent to EUR 22.9 million (20.9). Organic growth of 10 per cent, no impact from acquisitions and -1 per cent negative impact from currency movements.

Adjusted EBITA

Adjusted EBITA for the fourth quarter amounted to EUR 0.6 million (0.6) at a margin of 9.4 per cent (10.3).

The lower margin reflects the continued investments in diversifying the offering into companion animal diagnostics.

Adjusted EBITA for the period January to December amounted to EUR 2.2 million (2.2) at a margin of 9.5 per cent (10.5).

Quarterly revenue Diagnostics



Quarterly adjusted EBITA Diagnostics



Declaration of the Board of Directors and Chief Executive Officer

The Board of Directors and Chief Executive Officer declare that the interim report provides a true and fair view of the development of the Group's and parent company's business, its financial position and results, and describes significant risks and uncertainties faced by the parent company and the companies included in the Group.

Stockholm, 12 February 2026

Magnus Welander
Chairman

Gabriel Fitzgerald

Pia Marions

Petra Rumpf

Theodor Bonnier

Alireza Tajbakhsh
Group CEO

This report has not been reviewed by the company's auditors.

Prior to publication this information constituted inside information that Vimian Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the above contact persons, at 07:45 am CEST on 12 February 2026.

Webcast conference call on 12 February 2026: In connection with the interim report, Vimian will hold a webcast conference call in English at 09:00 am CEST. Vimian will be represented by CEO Alireza Tajbakhsh and CFO Carl-Johan Zetterberg Boudrie, who will present the interim report and answer questions. Information regarding telephone numbers is available at www.vimian.com/investors. The presentation will be available at www.vimian.com/investors after publication of the interim report. The webcast will be available at the same address after the live broadcast.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS

EURm unless otherwise stated	Note	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Revenue from contracts with customers	3, 4	109.0	104.9	425.0	374.8
Revenue		**109.0**	**104.9**	**425.0**	**374.8**
Other operating income	10	1.0	1.1	3.3	3.8
Raw material and merchandise		-35.3	-35.2	-132.2	-116.5
Other external expenses	10	-17.0	-23.2	-81.4	-83.0
Personnel expenses		-27.7	-25.7	-108.2	-94.9
Depreciation and amortisation		-10.1	-8.7	-37.9	-33.7
Other operating expenses		-0.6	-0.5	-1.8	-1.3
Operating profit		**19.2**	**12.5**	**66.8**	**49.2**
Net financial items		-7.5	2.5	-20.6	-20.3
Share of profit of an associate		-0.3	-	-0.3	0.0
Profit before tax		**11.4**	**14.9**	**45.9**	**28.9**
Income tax expense		0.8	-2.4	-13.5	-9.5
Profit for the period		**12.2**	**12.5**	**32.3**	**19.3**
Profit for the period attributable to:					
Equity holders of the parent		12.1	12.2	31.3	18.5
Non-controlling interests		0.1	0.3	1.1	0.8
Earnings per share, before dilution (EUR)		0.02	0.02	0.06	0.04
Earnings per share, after dilution (EUR)		0.02	0.02	0.06	0.04
Average number of shares, before dilution (Thousands)		527,920	523,891	525,701	503,823
Average number of shares, after dilution (Thousands)		527,920	524,564	525,701	504,496
Number of shares at the end of the period (Thousands)		529,263	523,891	529,263	523,891

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

EURm	Note	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Profit for the period		**12.2**	**12.5**	**32.3**	**19.3**
Other comprehensive income					
Items that may be reclassified to profit or loss:					
Exchange differences on translation of foreign operations		0.0	13.5	-41.5	7.2
Items that will not be reclassified to profit or loss:					
Remeasurement of defined benefit plans		-0.1	-	-0.0	0.0
Other comprehensive income for the period, net of tax		**-0.1**	**13.5**	**-41.5**	**7.2**
Total comprehensive income for the period, net of tax		**12.1**	**26.0**	**-9.2**	**26.5**
Total comprehensive income attributable to:					
Equity holders of the parent		11.8	25.6	-8.7	26.6
Non-controlling interests		0.4	0.4	-0.4	-0.1

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

EURm	Note	31 Dec 2025	31 Dec 2024
Non-current assets			
Goodwill		590.1	576.5
Intangible assets		238.9	226.3
Property, plant and equipment		31.6	28.6
Right-of-use assets		14.8	17.4
Investment in associates		14.1	9.1
Non-current financial assets		1.5	28.1
Deferred tax assets		5.2	1.0
Total non-current assets		**896.3**	**887.1**
Current assets			
Inventories		80.1	78.4
Trade receivables		57.3	55.2
Current tax receivables		1.2	2.5
Other receivables		6.7	11.7
Prepaid expenses and accrued income		13.2	10.0
Cash and cash equivalents		55.0	64.8
Total current assets		**213.5**	**222.7**
TOTAL ASSETS		1,109.8	1,109.8

EURm	Note	31 Dec 2025	31 Dec 2024
Equity			
Share capital		0.1	0.1
Other contributed capital		626.3	614.8
Reserves		-36.5	3.5
Retained earnings including this period’s profit		109.0	81.5
Total equity attributable to equity holders of the parent		**698.9**	**699.9**
Non-controlling interests		9.9	6.6
Total equity		**708.8**	**706.5**
Non-current liabilities			
Liabilities to credit institutions and bonds		223.3	215.9
Lease liabilities		10.3	13.0
Deferred tax liabilities		35.5	29.4
Other non-current liabilities	5	20.9	33.8
Non-current provisions		1.6	1.2
Total non-current liabilities		**291.6**	**293.4**
Current liabilities			
Liabilities to credit institutions and bonds		0.0	0.0
Lease liabilities		5.1	4.7
Trade payables		20.1	21.8
Current tax liabilities		10.3	6.9
Other current liabilities	5	53.9	58.3
Accrued expenses and prepaid income		19.2	18.1
Provisions		0.8	-
Total current liabilities		**109.4**	**109.9**
TOTAL EQUITY AND LIABILITIES		1,109.8	1,109.8

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Equity attributable to equity holders of the parent						
EURm	Share capital	Other contributed capital	Translation reserve	Retained earnings including this period's profit	Total equity attributable to equity holders of the parent	Non-controlling interests	Total equity
Opening balance 1 January 2024	**0.1**	**467.9**	**-4.6**	**63.1**	**526.4**	**0.3**	**526.7**
Profit for the period	-	-	-	18.5	18.5	0.8	19.3
Other comprehensive income	-	-	8.1	-	8.1	-0.9	7.2
Total comprehensive income	**-**	**-**	**8.1**	**18.5**	**26.6**	**-0.1**	**26.5**
Transactions with owners							
Share issue	0.0	148.6	-	-	148.6	-	148.6
Transaction costs	-	-1.7	-	-	-1.7	-	-1.7
Warrant programme	-	0.0	-	-	0.0	-	0.0
Transactions with non-controlling interests	-	-	-	-	-	6.3	6.3
Total	**0.0**	**146.9**	**-**	**-**	**146.9**	**6.3**	**153.3**
Closing balance 31 December 2024	**0.1**	**614.8**	**3.5**	**81.5**	**699.9**	**6.6**	**706.5**
Opening balance 1 January 2025	**0.1**	**614.9**	**3.5**	**81.5**	**699.9**	**6.6**	**706.5**
Profit for the period				31.3	31.3	1.1	32.3
Other comprehensive income			-40.0		-40.0	-1.5	-41.5
Total comprehensive income	**-**	**-**	**-40.0**	**31.3**	**-8.7**	**-0.4**	**-9.2**
Transactions with owners							
Share issue	0.0	10.5			10.5		10.5
Transaction costs		-0.1			-0.1		-0.1
Warrant program		1.1			1.1		1.1
Transactions with non-controlling interests				-3.7	-3.7	3.7	-
Total	**0.0**	**11.4**	**-**	**-3.7**	**7.7**	**3.7**	**11.4**
Closing balance 31 December 2025	**0.1**	**626.3**	**-36.5**	**109.0**	**698.9**	**9.9**	**708.8**

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

EURm	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Operating activities				
Operating profit	19.2	12.5	66.8	49.2
Adjustments for non-cash items	13.9	12.1	54.4	44.2
Interest received	-0.2	0.7	1.2	2.0
Interest paid	-5.7	-5.1	-15.7	-20.4
Paid income tax	-4.1	-3.3	-17.4	-15.1
Cash flow from operating activities before change in working capital	**23.2**	**16.9**	**89.3**	**60.0**
Change in inventories	0.9	2.8	-6.7	-0.3
Change in operating receivables	27.0	4.9	20.9	-9.2
Change in operating liabilities	4.6	-0.2	2.3	7.6
Cash flow from operating activities	**55.7**	**24.4**	**105.7**	**58.1**
Investing activities				
Acquisition of a subsidiary, net of cash acquired, Note 5 and 6	-5.0	-65.1	-92.2	-81.3
Investments in associates	-5.1	-0.0	-5.1	-1.2
Proceeds from sale of associates	0.1	0.0	0.1	-0.0
Investments in intangible assets	-2.4	-3.4	-6.0	-7.9
Investments in property, plant and equipment	-3.4	-2.3	-9.1	-6.3
Proceeds from sale of property, plant and equipment	0.1	0.0	0.1	0.1
Investments in / sales of other financial assets	-1.8	101.4	-0.5	20.7
Cash flow from investing activities	**-17.5**	**30.5**	**-112.8**	**-76.0**
Financing activities				
New share issue	0.4	-	10.5	142.7
Warrant program	-0.4	-0.0	-0.0	0.0
Transaction costs	-0.0	0.0	-0.1	-1.7
Proceeds from borrowings	5.5	1.9	277.8	80.4
Repayment of borrowings	-39.2	-30.5	-284.1	-172.9
Payment of lease liabilities	-1.3	-1.2	-4.9	-3.7
Transactions with non-controlling interests	-0.4	-	-0.4	-
Cash flow from financing activities	**-35.5**	**-29.8**	**-1.2**	**44.8**
Cash flow for the period	**2.7**	**25.1**	**-8.3**	**26.9**
Cash and cash equivalents at beginning of the period	51.3	39.2	64.8	37.5
Exchange-rate difference in cash and cash equivalents	1.1	0.2	-1.5	0.2
Cash and cash equivalents at end of the period	**55.0**	**64.8**	**55.0**	**65.0**

CONDENSED PARENT COMPANY INCOME STATEMENT AND BALANCE SHEET

SEKm	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Revenue	25.5	12.8	61.0	52.3
Other operating income	-	-	-	-
Total operating income	**25.5**	**12.8**	**61.0**	**52.3**
Other external expenses	-10.2	-14.3	-48.9	-43.2
Personnel expenses	-12.3	-15.2	-75.7	-51.4
Depreciation and amortisation	-0.7	-0.7	-2.9	-0.8
Other operating expenses	-0.3	-0.2	-2.1	-2.5
Operating profit	**1.9**	**-17.7**	**-68.6**	**-45.6**
Group contributions	285.4	-95.0	285.4	-95.0
Net financial items[1]	-35.0	223.8	-212.4	371.7
Profit before tax	**252.3**	**111.2**	**4.5**	**231.1**
Income tax expense	**40.6**	**-**	**24.4**	**-**
Profit for the period	**292.9**	**111.2**	**28.9**	**231.1**

[1] Net financial items for the year includes interest income of SEK 337.2m (397.9), dividend from subsidiary 95.0 (0), interest expenses (including bank fees) of SEK -167.0m (-210.8) and exchange rate differences of SEK -477.6m (184.8).

SEKm	31 Dec 2025	31 Dec 2024
ASSETS		
Non-current assets		
Intangible assets	10.3	13.1
Property, plant and equipment	0.2	0.3
Shares in subsidiaries	6,254.3	6,246.4
Non-current group receivables	6,840.1	6,936.9
Other non-current assets	40.6	-
Total non-current assets	**13,145.5**	**13,196.7**
Current assets		
Group receivables	399.2	107.0
Other receivables	2.5	10.6
Prepaid expenses and accrued income	82.9	2.1
Total current assets	**484.6**	**119.7**
TOTAL ASSETS	**13,630.1**	**13,316.4**
Equity		
Share capital	0.9	0.9
Development fund	10.3	13.1
Fair value fund	2.5	-
Share premium	8,381.5	8,264.7
Retained earnings	2,083.7	1,839.8
Profit for the period	28.9	231.1
Total equity	**10,507.8**	**10,349.6**
Non-current liabilities		
Liabilities to credit institutions and bonds	2,388.7	2,475.4
Group non-current liabilities	-	0.6
Total non-current liabilities	**2,388.7**	**2,475.9**
Current liabilities		
Group payables	680.7	471.0
Trade payables	6.7	4.4
Other current liabilities	24.2	1.8
Accrued expenses and prepaid income	22.0	13.7
Total current liabilities	**733.6**	**490.9**
TOTAL EQUITY AND LIABILITIES	**13,630.1**	**13,316.4**

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Significant accounting policies

The interim condensed consolidated financial statements comprise of the Swedish parent company Vimian Group AB (publ), with corporate identity number 559234-8923, and its subsidiaries. The Group's primary operations are offering products and services in animal health for domestic pets and livestock around the world. The Group offers goods and services in medicine, diagnostics and medtech as well as services and advice for veterinary professionals. The Parent Company is a limited liability company with its registered office in Stockholm, Sweden. The address of the head office is Riddargatan 19, 114 57 Stockholm.

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and interpretations issued by the IFRS Interpretations Committee (IFRS IC) as adopted by the European Union (EU) and RFR1.

The Group's interim report is prepared in accordance with IAS 34 Interim financial reporting and applicable parts of the Swedish Annual Accounts Act (1995:1554). The interim report of the parent company is prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim financial reporting and Recommendation RFR 2 Accounting for Legal Entities. The Group and Parent Company have applied the same accounting principles, basis of calculation, and assumptions as those applied in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2024.

For a complete description of the Group's and Parent Company's applied accounting principles, see note 1 of the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2024. Disclosures according to IAS 34 are presented in the financial statements as well as corresponding notes on page 12-21, which are an integrated part of the interim condensed consolidated financial statements. All amounts are presented in millions of Euro ("MEUR"), unless otherwise indicated.

Note 2. Key estimates and assumptions

In preparing the interim financial statements, corporate management and the Board of Directors must make certain assessments and assumptions that impact the carrying amount of asset and liability items and revenue and expense items, as well as other information provided. The actual outcome may then differ from these assessments if other conditions arise. The key estimates and assumptions correspond to the ones described in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2024.

Significant estimates during the financial year 2025 concerns the value of the non-current receivable related to the US patent litigation. On 4 April 2023, Vimian's subsidiary Veterinary Orthopedic Implants LLC ("VOI") reached a settlement agreement with DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. resolving the patent dispute between the parties. Under the terms of the agreement, Vimian paid USD 70 million during the second quarter of 2023.

In the indemnification dispute with the VOI sellers, VOI entered into settlement agreements with three of the four sellers in 2024. Each of the three sellers has agreed to compensate Vimian for their entire pro rata shares of the USD 70 million settlement payment to DePuy Synthes. The total value of the three settlements amounts to approximately USD 32 million of which approximately USD 9 million has been contributed by means of dismissal of the contingent closing note from the acquisition of VOI.

On 29 August 2025, the Superior Court of Delaware awarded Vimian USD 40.2 million in damages in the indemnification dispute with the largest seller of VOI. On 1 October the court confirmed the decision from 29 August and also awarded Vimian prejudgement interest of USD 8.6 million. Together with the previously reached settlements with the other sellers, this means that Vimian is entitled to compensation exceeding the USD 70 million settlement paid by Vimian to DePuy Synthes. The largest seller has appealed the court decision. The trial in the Supreme Court of Delaware is expected in 2026. During Q4 2025, the largest seller paid USD 31.9 million. The remaining debt from the largest seller amounts to USD 6.2 million.

The payments received exceed the reported receivables on the seller by EUR 2.9 million. This was netted off litigation costs of EUR 6.1 million in the 2025 result, reported as items affecting comparability. Vimian has not reported a provision for the on-going litigation and has also considered the remaining receivable on the seller as doubtful and therefore has not recorded any value in the financial statements. The payment of the receivable was reported as change in operating receivables within cash flow from operating activities in the fourth quarter.

Note 3. Operating segments

mEUR Oct-Dec 2025	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	46.0	40.1	6.1	16.8	109.0	-	-	109.0
Revenue from internal customers	0.0	0.1	-	0.1	0.1	-	-0.1	-
Total revenue	**46.0**	**40.2**	**6.1**	**16.9**	**109.1**	**-**	**-0.1**	**109.0**
Adjusted EBITA	**13.8**	**9.9**	**0.6**	**4.5**	**28.7**	**-2.6**	**-0.0**	**26.1**
Items affecting comparability	-0.1	0.5	-0.5	-0.2	-0.4	-0.3	-	-0.7
EBITA	**13.7**	**10.4**	**0.0**	**4.2**	**28.3**	**-2.9**	**-0.0**	**25.4**
Amortisation of acquisition-related intangible assets	-3.0	-2.3	-0.2	-0.7	-6.2	-	-	-6.2
Net financial items	-3.5	-5.3	-0.0	-0.7	-9.6	6.4	-4.3	-7.5
Share of profit of an associate and joint venture	-	-	-0.3	-	-0.3	-	-	-0.3
Profit before tax	**3.4**	**-3.4**	**-0.6**	**-6.7**	**-7.3**	**23.0**	**-4.3**	**11.4**
Specification of items affecting comparability								
Acquisition-related costs[1]	0.0	0.4	0.5	0.2	1.1	-	-	1.1
Systems update	-	0.2	-	0.0	0.2	-	-	0.2
Restructuring costs[2]	0.1	1.6	-	0.1	1.8	-	-	1.8
IPO and financing related costs	-	-	-	-	-	0.0	-	0.0
Other[3]	0.0	-2.7	-	-	-2.7	0.3	-	-2.4
Total items affecting comparability	**0.1**	**-0.5**	**0.5**	**0.2**	**0.4**	**0.3**	**-**	**0.7**
Other disclosures								
Investments	1.9	0.7	0.3	0.5	3.3	-	-	3.3
Total assets	516.3	450.2	56.9	167.1	1,190.6	722.9	-803.6	1,109.8
Total liabilities	346.4	345.6	39.5	142.7	874.2	330.4	-803.6	401.0

[1] In Diagnostics the acquisition related costs relate to the acquisitions of I-Vet, announced in Q4-2025.
[2] In MedTech the main item refers to write-down of inventories of sunset product range.
[3] Main items in other refers to payments net of litigation costs in the US indemnification dispute.

mEUR Oct-Dec 2024	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	45.2	38.4	5.9	15.4	104.9	-	-	104.9
Revenue from internal customers	0.0	0.0	-	0.1	0.1	-0.0	-0.1	-
Total revenue	**45.2**	**38.4**	**5.9**	**15.5**	**105.0**	**-0.0**	**-0.1**	**104.9**
Adjusted EBITA	**13.3**	**8.0**	**0.6**	**5.0**	**26.9**	**-2.4**	**-**	**24.6**
Items affecting comparability	-2.8	-2.4	-0.0	-0.5	-5.8	-0.4	-	-6.2
EBITA	**10.4**	**5.6**	**0.6**	**4.5**	**21.1**	**-2.8**	**-**	**18.3**
Amortisation of acquisition-related intangible assets	-3.1	-1.7	-0.2	-0.7	-5.8	-	-	-5.8
Net financial items	-2.9	-9.4	-0.3	-2.1	-14.7	17.1	-	2.5
Share of profit of an associate and joint venture	-	-	-	-	-	-	-	-
Profit before tax	**6.7**	**-1.6**	**0.0**	**3.5**	**8.6**	**6.3**	**-**	**14.9**
Specification of items affecting comparability								
Acquisition-related costs[1]	2.5	0.6	0.0	-0.0	3.1	-	-	3.1
Systems update	-	0.0	-	0.0	0.0	-	-	0.0
Restructuring costs	0.3	-	-0.0	-0.0	0.3	-	-	0.3
IPO and financing related costs	-	-	0.0	-	0.0	0.4	-	0.4
Other[2]	0.0	1.8	0.0	0.5	2.3	0.0	-	2.3
Total items affecting comparability	**2.8**	**2.4**	**0.0**	**0.5**	**5.8**	**0.4**	**-**	**6.2**
Other disclosures								
Investments	2.4	1.9	0.9	0.5	5.7	-	-	5.7
Total assets	525.7	421.4	54.9	166.1	1,168.1	658.9	-717.2	1,109.8
Total liabilities	363.1	281.5	36.6	137.5	818.7	301.8	-717.2	403.3

[1] In Specialty Pharma, EUR 0.9m of the acquisition-related costs are stay-on bonuses, reported as personnel costs, to management of acquired companies. In Medtech, the majority of the acquisition related costs relate to the acquisition of iM3, closed in Q4.
[2] Main items in other are legal fees related to the VOI litigation and costs related to the uplisting to Nasdaq Stockholm Main Market.

mEUR Jan-Dec 2025	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	182.4	155.5	22.9	64.3	425.0	-	-	425.0
Revenue from internal customers	0.0	0.1	-	0.2	0.4	-	-0.4	-
Total revenue	**182.4**	**155.5**	**22.9**	**64.5**	**425.4**	**-**	**-0.4**	**425.0**
Adjusted EBITA	**53.9**	**39.6**	**2.2**	**18.4**	**114.1**	**-8.8**	**-0.0**	**105.3**
Items affecting comparability	-0.6	-9.7	-0.7	-0.4	-11.4	-3.2	-	-14.7
EBITA	**53.3**	**29.9**	**1.4**	**18.0**	**102.7**	**-12.0**	**-0.0**	**90.7**
Amortisation of acquisition-related intangible assets	-12.3	-7.9	-0.9	-2.8	-23.8	-	-	-23.8
Net financial items	-9.0	-20.6	-0.5	-1.2	-31.3	19.0	-8.3	-20.7
Share of profit of an associate and joint venture	-	-	-0.3	-	-0.3	-	-	-0.3
Profit before tax	**28.3**	**-4.9**	**-0.3**	**4.5**	**27.7**	**26.5**	**-8.3**	**45.9**
Specification of items affecting comparability								
Acquisition-related costs[1]	0.2	2.9	0.7	0.3	4.1	-	-	4.1
Systems update	-	0.9	-	0.0	0.9	-	-	0.9
Restructuring costs[2]	0.4	1.8	-	0.1	2.2	-	-	2.2
IPO and financing related costs	-	-	-	-	-	0.6	-	0.6
Other[3]	0.1	4.2	0.0	-	4.2	2.6	-	6.8
Total items affecting comparability	**0.6**	**9.7**	**0.7**	**0.4**	**11.4**	**3.2**	**-**	**14.7**
Other disclosures								
Investments	7.8	3.4	1.6	2.5	15.3	-	-	15.3
Total assets	516.3	450.2	56.9	167.1	1,190.6	722.9	-803.6	1,109.8
Total liabilities	346.4	345.6	39.5	142.7	874.2	330.4	-803.6	401.0

[1] In Medtech the majority of the acquisition related costs relate to the acquisitions of iM3, AllAccem and Dental Focus.
[2] In MedTech the main item refers to write-down of inventories of sunset product range.
[3] Main items in other are legal fees related to the VOI litigation net of payment from largest seller in MedTech and provision for compensation to participants in the LTI 2022 programme in Central

EURm Jan-Dec 2024	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	172.0	123.9	20.9	58.0	374.8	-	-	374.8
Revenue from internal customers	0.0	0.0	-	0.2	0.3	-	-0.3	-
Total revenue	**172.0**	**123.9**	**20.9**	**58.2**	**375.1**	**-**	**-0.3**	**374.8**
Adjusted EBITA	**49.2**	**34.3**	**2.3**	**16.9**	**102.7**	**-7.4**	**0.0**	**95.2**
Items affecting comparability	-7.0	-14.3	-0.1	-1.1	-22.5	-1.2	-	-23.7
EBITA	**42.2**	**20.0**	**2.2**	**15.8**	**80.2**	**-8.6**	**0.0**	**71.6**
Amortisation of acquisition-related intangible assets	-12.5	-6.0	-0.9	-3.0	-22.3	-	-	-22.3
Net financial items	-24.1	-17.3	-1.6	-11.0	-54.0	33.6	-	-20.3
Share of profit of an associate and joint venture	-	-	-	0.0	0.0	-	-	0.0
Profit before tax	**7.9**	**0.6**	**-0.3**	**3.7**	**11.9**	**17.0**	**-0.0**	**28.9**
Specification of items affecting comparability								
Acquisition-related costs[1]	5.4	3.0	0.0	0.5	9.0	-	-	9.0
Systems update	-	1.1	-	0.1	1.2	-	-	1.2
Restructuring costs	1.2	-	0.0	0.0	1.3	-	-	1.3
IPO and financing related costs	-	-	0.0	-	0.0	0.5	-	0.5
Other[2]	0.3	10.2	0.0	0.5	11.0	0.7	-	11.6
Total items affecting comparability	**7.0**	**14.3**	**0.1**	**1.1**	**22.5**	**1.2**	**-**	**23.7**
Other disclosures								
Investments	6.6	3.8	2.1	1.7	14.2	-	-	14.2
Total assets	525.7	421.4	54.9	166.1	1,168.1	658.9	-717.2	1,109.8
Total liabilities	363.1	281.5	36.6	137.5	818.7	301.8	-717.2	403.3

[1] In Specialty Pharma, EUR 2.9m of the acquisition-related costs are stay-on bonuses, reported as personnel costs, to management of acquired companies.
[2] Main items in other are legal fees related to the VOI litigation and cost related to the uplisting to Nasdaq Stockholm Main Market.

Note 4. Revenue from contracts with customers

EURm Oct-Dec 2025	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Geographic region					
Europe	26.2	13.4	3.9	12.7	56.2
North America	16.3	20.3	0.9	3.2	40.6
Rest of the World	3.5	6.4	1.3	0.9	12.2
Revenue from contracts with customers	**45.9**	**40.1**	**6.1**	**16.8**	**109.0**

EURm Oct-Dec 2024	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Geographic region					
Europe	22.8	12.1	3.7	11.7	50.3
North America	18.4	20.1	1.2	2.8	42.4
Rest of the World	3.6	6.2	1.0	0.9	11.8
Revenue from contracts with customers	**44.8**	**38.4**	**5.9**	**15.4**	**104.5**

EURm Jan-Dec 2025	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Geographic region					
Europe	101.8	48.7	14.2	50.3	215.0
North America	67.2	80.6	3.8	10.8	162.3
Rest of the World	13.4	26.2	4.9	3.2	47.7
Revenue from contracts with customers	**182.4**	**155.5**	**22.9**	**64.3**	**425.0**

EURm Jan-Dec 2024	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Geographic region					
Europe	92.0	31.7	12.7	45.7	182.1
North America	67.4	72.2	3.6	9.4	152.7
Rest of the World	12.2	20.0	4.6	2.9	39.7
Revenue from contracts with customers	**171.6**	**123.9**	**20.9**	**58.0**	**374.4**

The group has significant exposure to the US, 36 per cent (38) and the UK, 13 per cent (12) markets. All other markets individually represent less than 10 per cent of net revenue. Net revenue from external customers in Sweden amounted to EUR 17.1m (16.0) 2025. No individual customer accounts for more than 10 per cent of Group net revenue.

On Group level, 79 per cent (79) of net sales in the fourth quarter is generated from products sold whilst 21 per cent (21) of net sales is generated from services. Most of sales in Specialty Pharma, MedTech and Diagnostics consist of products sold, except for trainings, testing and repairs which qualifies as a service (during the fourth quarter revenue from services amounted to 13 per cent (15) of Specialty Pharma, 2 per cent (1) of Medtech and 2 per cent (2) of Diagnostics). Most of sales in Veterinary Services consists of services, although 7 per cent (7) of the segment's revenue comes from products sold through the co-owned veterinary clinics.

Note 5. Financial instruments

The carrying amount of the Group's financial instruments measured at fair value regards contingent considerations (see below). The carrying amount of other financial assets and liabilities is deemed to be a good approximation of the fair value.

Contingent consideration

In some of the Group's business combinations, part of the purchase price has been in the form of contingent consideration. The contingent considerations depend on the future earnings or sales of the acquired companies.

The contingent considerations will be settled in cash. The contingent considerations are included in the following line items in the statement of financial position for 31 December 2025: other non-current liabilities EUR 20.4 million (28.3) and other current liabilities EUR 26.1 million (35.3). The contingent considerations are measured at fair value by discounting the expected cash flows by a risk adjusted discount rate. The contingent considerations are classified as level 3 in the fair value hierarchy.

The contingent considerations consist of earn-out agreements in business combinations. The earn-out hurdles are typically linked to sales or EBITDA targets for periods ranging 1-5 years after the acquisition date. The earn-outs are discounted and revaluated on an ongoing basis, based on the current performance and forecasted figures for the acquired companies.

There are currently 27 separate obligations, all with their own targets, capped at a maximum amount. The maximum amount payable if all acquisitions would reach their capped amounts is EUR 113.2 million. A 10 per cent increase in the underlying metric (sales or EBITDA) for all acquisitions compared to the current assumptions would lead to an increase of the contingent consideration of EUR 8.1 million.

Contingent consideration, EURm	Jan-Dec 2025	Jan-Dec 2024
Opening balance	**63.7**	**47.7**
Business combinations	8.3	20.4
Paid out	-33.6	-13.9
Change in fair value recognised in P&L	5.5	10.1
Probability adjustments recognised in the P&L	4.1	-1.5
Exchange differences on translation of foreign operations	-1.5	1.0
Closing balance	**46.4**	**63.7**

Note 6. Business combinations

The following acquisitions have been completed during the period January – December 2025:

EURm	Deal type	Acquired %	Based	Segment	Consolidation month	Annual sales
Dental Focus LLC	Share	100%	United States	Medtech	Apr	2.0
AllAccem Inc	Share	100%	United States	Medtech	Jun	9.0
Blossom Vets BV	Share	100%	Belgium	Veterinary services	Nov	0.9

Dental Focus LLC

On 1 April 2025, the Group acquired 100% of the shares in Dental Focus LLC. Dental Focus is a highly reputable provider of veterinary dental imaging equipment and services, primarily x-ray units and sensors. Dental Focus has annual sales of around USD 2 million.

AllAccem Inc

On 13 June 2025, the Group acquired 100% of the shares in AllAccem Inc. AllAccem Inc is a leading provider of a veterinary dental sealant product in the US. AllAccem Inc. had revenues of around USD 9 million for the twelve months ending April 2025.

Blossom Vets BV

On 1 November 2025, the Group acquired 100% of the shares in Blossom Vets BV. Blossom Vets BV has annual revenues of around EUR 0.9 million.

Preliminary purchase price allocations per operating segment during the period January – December 2025

Acquired net assets on acquisition date based on preliminary PPA, EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Intangible assets		41.4		1.6	43.0
Property, plant and equipment		1.0			1.0
Right-of-use assets		-			-
Non-current financial assets		-			-
Deferred tax assets		-			-
Inventories		0.2			0.2
Trade receivable and other receivables		1.0		0.8	1.8
Cash and cash equivalents		0.5		0.1	0.6
Interest-bearing liabilities		-			-
Lease liabilities		-			-
Deferred tax liabilities		-11.5		-0.4	-11.9
Trade payables and other operating liabilities		-0.2		-0.4	-0.6
Identified net assets		**32.4**		**1.8**	**34.2**
Non-controlling interest measured at fair value		-		-	-
Goodwill		30.0		1.0	31.0
Total purchase consideration		**62.4**		**2.7**	**65.2**
Purchase consideration comprises:					
Cash		54.2		2.3	56.6
Equity instruments		-			-
Contingent consideration and deferred payments		8.2		0.4	8.6
Total purchase consideration		**62.4**		**2.7**	**65.2**

Impact of acquisition on Group's cash flow, EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Cash portion of purchase consideration		54.2		2.3	56.6
Acquired cash		-0.5		-0.1	-0.6
Total		**53.8**		**2.2**	**55.9**
Acquisition-related costs		1.0		0.1	1.1
Net cash outflow		**54.7**		**2.3**	**57.0**

The purchase price allocations of Dental Focus, AllAccem and Blossom Vets are deemed preliminary. The group does not expect any material deviations from the current numbers.

Note 7. Related-party transactions

There have been no significant changes in the relationships with related parties for the Group or the Parent Company compared to the information provided in the Annual Financial statements for 2024. All related party transactions are at arm's length.

Year-to-date transactions with minority interests within the diagnostics segment amounted to EUR 0.4m, being a loan.

Year to date an amount of EUR 9.7m in licensing income was invoiced to an entity owned by Nick Bova, manager within the Specialty Pharma segment, that owns Pharmacy licenses as part of regulatory restrictions.

Other related party transactions include rent and fee payments to former owners of acquired businesses. The amounts paid in these transactions are insignificant both individually and as a whole. Additionally, the company has received settlement payments from the seller of VOI, totalling EUR 0.8m.

Note 8. Events after the balance-sheet date

On 12 January, Vimian announced that Magnus Kjellberg, Head of Specialty Pharma, decided to step down during spring and that Carl-Johan Zetterberg Boudrie is appointed interim Head of Specialty Pharma in addition to his position as CFO.

Note 9. Seasonal effects and risks

Seasonal effects

Vimian assesses that its revenues and EBITA to a limited degree are affected by seasonality. The four segments have varying, but limited, seasonality patterns. The strongest seasonality effect can be seen in MedTech, where the first quarter is typically the strongest quarter due to the AOP programme. During 2024 and 2025 Vimian have reduced the AOP to better align shipments with customer demand for the MedTech segment. As a consequence, the revenue will be more evenly spread throughout the year with limited seasonality for MedTech. For all segments, trading volumes are slightly negatively affected by holiday periods.

Risks and uncertainties

Vimian Group's and the parent company's business risks and risk management, as well as the management of financial risks, are described on pages 48-55 in the 2024 Annual Report published at www.vimian.com.

The group has limited exposure to the current geopolitical environment, mainly being the international supply chain for both finished products and raw materials. In case of tariffs or conflicts this could hurt the groups competitive advantage in certain businesses. To mitigate these risks the group is diversifying its supply chains and implementing contingency plans.

Note 10. Restatement of Statement of profit and loss

As from the fourth quarter 2025, Vimian has changed the accounting of elimination of internal management fees. The elimination was previously netting Other operating income and Other external expenses. The change has no other effect on the financial statements. Comparative periods have been restated accordingly.

EURm	Other operating income		Other external expenses	
	Reported	Restated	Reported	Restated
Jan-Mar 2024	0.9	2.1	-19.7	-20.9
Apr-Jun 2024	0.1	0.6	-19.3	-19.8
Jan-Jun 2024	-0.2	1.5	-37.9	-39.6
Jul-Sep 2024	-0.1	1.1	-19.0	-20.2
Jan-Sep 2024	-0.2	2.7	-56.9	-59.8
Oct-Dec 2024	0.1	1.1	-22.3	-23.2
Jan-Dec 2024	-0.1	3.8	-79.2	-83.0
Jan-Mar 2025	-0.1	0.7	-23.1	-23.9
Apr-Jun 2025	-0.1	1.0	-20.6	-21.7
Jan-Jun 2025	-0.2	1.7	-43.8	-45.7
Jul-Sep 2025	-0.1	0.6	-18.0	-18.7
Jan-Sep 2025	-0.3	2.3	-61.8	-64.4

ALTERNATIVE PERFORMANCE MEASURES

Alternative Performance Measures (APMs) are financial measures of historical or future financial performance, financial position or cash flows that are not defined in applicable accounting regulations (IFRS). APMs are used by Vimian when it is relevant to monitor and describe Vimian's financial situation and to provide additional useful information to users of financial statements. These measures are not directly comparable to similar key ratios presented by other companies.

Key Ratios	Definition	Reason for usage
Organic Revenue Growth	Change in Revenue in relation to the comparative period adjusted for acquisition and divestment effects and any currency impacts. Acquired businesses are included in Organic growth when they have been part of the Group for 12 months and divested businesses are excluded from Organic growth from the date of divestment in the current and comparative period. The Currency impact is calculated by translating the accounts for year N-1 of subsidiaries having a functional currency different than the currency of the issuer with N exchange rate.	Organic growth is used by investors, analysts and the company's management to monitor the underlying development of revenue between different periods at constant currency and excluding the impact of any acquisitions and/or divestments.
EBIT	Operating profit as reported in the Income statement, i.e. profit for the period excluding finance income, finance costs, share of profit of an associate and income tax expense.	The measure shows the profitability from the operations of the parent company and its subsidiaries.
EBITA	Operating profit excluding amortisation of intangible assets that were originally recognised in connection with business combinations.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company's financing structure.
EBITDA	Operating profit excluding amortisation, depreciation and impairment of intangible and tangible assets.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure.
Adjusted EBITA	EBITA adjusted for items affecting comparability.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company's financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITA margin	Adjusted EBITA in relation to Revenue.	The measure reflects the business's operating profitability before amortisation of intangible assets. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITDA	EBITDA adjusted for items affecting comparability.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITDA margin	Adjusted EBITDA in relation to Revenue.	The measure reflects the business's operating profitability before amortisation and depreciation of intangible and tangible fixed assets. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Items affecting comparability	Income and expense items that are considered to be important to specify to users of the financial information since they affect comparability.	A separate disclosure of items affecting comparability is relevant to provide to users of the financial information to give further understanding of the financial performance when comparing of financial performance between periods. Generally accepted NRI's include acquisition and integration related costs, litigation related costs if material, significant restructuring costs (e.g., the consolidation of production footprint in Diagnostics going from four to two production sites), costs related to projects such as the initial public offering.

Key Ratios	Definition	Reason for usage
Amortisation PPA related	Amortisation of intangible assets that were originally recognised in connection with business combinations.	Specification of amortisation in different categories since management differentiates amortisation when calculating EBITA.
Net debt	Cash and cash equivalents less liabilities to credit institutions, lease liabilities, other non-current liabilities and specific items included in other current liabilities (contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations).	Net debt is a measure used to follow the development of debt and the size of the refinancing need. Since cash and cash equivalents can be used to pay off debt at short notice, net debt is used instead of gross debt as a measure of the total loan financing.
Net debt / Adjusted EBITDA (pro-forma)	Net debt in relation to a 12-month period of Adjusted EBITDA (pro-forma).	The measure is a debt ratio that shows how many years it would take to pay off the Company's debt, provided that its net debt and Adjusted EBITDA are constant and without taking into account the cash flows regarding interest, taxes and investments. Net Debt / Adjusted EBITDA is referred to in the report as leverage.
Net Working Capital	Inventory, Trade receivables, Current tax receivables, Other current receivables, Prepaid expenses and Accrued income, less Trade payables, Current tax liabilities, Accrued expenses and deferred income, Provisions and Other current liabilities (excluding contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations)	Working capital is a measure of the company's short-term financial status
Capex	Total cash flow from investments in tangible and intangible assets during the period. This includes costs for internally developed assets.	Capex is a measure of the company's historical investments and is used as input in calculating Free cash flow and Cash conversion.
Proforma revenue	Reported revenue for the last twelve months plus revenue for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects a fair view of the business's revenue for a full year period.
Adjusted EBITA, Proforma	Reported adjusted EBITA for the last twelve months adding the adjusted EBITA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Adjusted EBITDA, Proforma	Reported adjusted EBITDA for the last twelve months adding the adjusted EBITDA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Adjusted EBITA and EBITDA margin, Proforma	Adjusted proforma EBITA and EBITDA in relation to proforma revenue.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Acquisition related expenses	Expenses related to legal and financial due diligence as well as in some cases stay on bonuses to key personnel. If specific initial integration costs are required, and agreed upon during the acquisition process, this can be considered as acquisition related expenses.	
Restructuring costs	Costs relating to significant change of business model or operational structure. Possibly linked to integration between legacy and acquired businesses. The most significant restructuring project to date is the consolidation of production footprint in Diagnostics going from four to two production sites.	

Alternative performance measures not defined in accordance with IFRS for the group - Based on reported figures

	1 Oct-31 Dec		1 Jan-31 Dec	
EURm (unless otherwise stated)	2025	2024	2025	2024
Revenue growth (%)	4%	27%	13%	13%
Organic revenue growth (%)	6%	15%	6%	9%
Revenue	109.0	104.9	425.0	374.8
EBITDA	29.4	21.3	104.8	82.9
EBITDA margin (%)	27.0%	20.3%	24.7%	22.1%
Items affecting comparability	0.7	6.2	14.7	23.7
Adjusted EBITDA	30.0	27.5	119.5	106.6
Adjusted EBITDA margin (%)	27.6%	26.2%	28.1%	28.4%
EBITA	25.4	18.3	90.7	71.6
EBITA margin (%)	23.4%	17.5%	21.3%	19.1%
Adjusted EBITA	26.1	24.6	105.3	95.2
Adjusted EBITA margin (%)	24.0%	23.4%	24.8%	25.4%
Operating profit	19.2	12.5	66.8	49.2
Operating margin (%)	17.7%	12.0%	15.7%	13.1%
Capital expenditure	-5.8	-5.7	-15.1	-14.2
Cash flow from operating activities	55.7	24.4	105.7	58.1

Alternative performance measures not defined in accordance with IFRS for the group - Based on proforma figures

	1 Jan - 31 Dec
EURm (unless otherwise stated)	LTM (2024/2025)
Proforma revenue	430.4
Adjusted EBITDA, Proforma	123.1
Adjusted EBITDA margin, Proforma	28.6%
Net debt	245.4
Net debt / Adjusted EBITDA, Proforma (x)	2.0x

Reconciliation of alternative performance measures not defined in accordance with IFRS for the group

Certain statements and analyses presented include alternative performance measures (APMs) that are not defined by IFRS. The Company believes that this information, together with comparable defined IFRS metrics, are useful to investors as they provide a basis for measuring operating profit and ability to repay debt and invest in operations. Corporate management uses these financial measurements, along with the most directly comparable financial metrics under IFRS, to evaluate operational results and value added. The APMs should not be assessed in isolation from, or as a substitute for, financial information presented in the financial statements in accordance with IFRS. The APMs reported are not necessarily comparable to similar metrics presented by other companies. The reconciliations are presented in the tables below:

	1 Oct-31 Dec		1 Jan-31 Dec	
EURm (unless otherwise stated)	**2025**	**2024**	**2025**	**2024**
EBITA/EBITDA and Adjusted EBITA/EBITDA				
Revenue	109.0	104.9	425.0	374.8
EBIT	19.2	12.5	66.8	49.2
Amortisation of acquisition related intangibles	6.2	5.8	23.8	22.3
EBITA	25.4	18.3	90.7	71.6
Other depreciation	3.9	2.9	14.1	11.3
EBITDA	29.4	21.3	104.8	82.9
Items affecting comparability	0.7	6.2	14.7	23.7
Adjusted EBITA	26.1	24.6	105.3	95.2
Adjusted EBITDA	30.0	27.5	119.5	106.6
EBITA margin (%)	**23.4%**	**17.5%**	**21.3%**	**19.1%**
EBITDA margin (%)	**27.0%**	**20.3%**	**24.7%**	**22.1%**
Adjusted EBITA margin (%)	**24.0%**	**23.4%**	**24.8%**	**25.4%**
Adjusted EBITDA margin (%)	**27.6%**	**26.2%**	**28.1%**	**28.4%**

	31 Dec	
EURm (unless otherwise stated)	**2025**	**2024**
Net debt		
Liabilities to credit institutions (long term)	223.3	215.9
Lease liabilities (long term)	10.3	13.0
Other non-current liabilities	20.9	33.8
Liabilities to credit institutions (short term)	0.0	0.0
Lease liabilities (short term)	5.1	4.7
Other items[1]	42.3	47.4
Cash & Cash Equivalents	-55.0	-64.8
Other receivables[2]	-1.5	-28.1
Net debt	**245.4**	**222.0**

	31 Dec	
EURm (unless otherwise stated)	**2025**	**2024**
Net working capital		
Inventory	80.1	78.4
Trade receivables	57.3	55.2
Current tax receivables	1.2	2.5
Other current receivables	6.7	11.7
Prepaid expenses and accrued income	13.2	10.0
Trade payables	-20.1	-21.8
Current tax liabilities	-10.3	-6.8
Other current liabilities[3]	-11.5	-11.0
Provisions	-0.8	-0.2
Accrued expenses and deferred income	-19.2	-18.1
Net working capital	**96.6**	**100.1**

[1] Shareholder loans, deferred payments, vendor notes and contingent considerations included in other current liabilities
[2] Other receivables related to the US patent litigation
[3] Other current liabilities as reported in the statement of financial position less shareholder loans, deferred payments, vendor notes and contingent considerations related to business combinations

EURm (unless otherwise stated)	1 Jan - 31 Dec LTM (2024/2025)	1 Jan-31 Dec 2024
Proforma revenue		
Reported revenue	425.0	374.8
Proforma period, revenue	5.3	27.2
Proforma revenue	**430.4**	**402.0**
Adjusted EBITA, Proforma		
Reported Adjusted EBITA (12 months)	105.3	95.2
Proforma period Adjusted EBITA	3.6	5.5
Adjusted EBITA, Proforma	**108.9**	**100.7**
Adjusted EBITA margin, Proforma		
Proforma Revenue	430.4	402.0
Adjusted EBITA, Proforma	108.9	100.7
Adjusted EBITA margin, Proforma	**25.3%**	**25.0%**
Adjusted EBITDA, Proforma		
Reported Adjusted EBITDA (12 months)	119.5	106.6
Proforma period Adjusted EBITDA	3.7	5.8
Adjusted EBITDA, Proforma	**123.1**	**112.4**
Adjusted EBITDA margin, Proforma		
Proforma Revenue	430.4	402.0
Adjusted EBITDA, Proforma	123.1	112.4
Adjusted EBITDA margin, Proforma	**28.6%**	**28.0%**
Net debt/Adjusted EBITDA, Proforma		
Net debt	245.4	221.9
Adjusted EBITDA, Proforma	123.1	112.4
Net debt/Adjusted EBITDA, Proforma (x)	**2.0x**	**2.0x**

Financial calendar

19 March 2026
Annual Report
29 April 2026
Interim Report Q1 2026
Annual General Meeting
17 July 2026
Interim Report Q2 2026

For further information, please contact

Carl-Johan Zetterberg Boudrie
CFO and interim CEO
carl-johan.zetterberg@vimian.com
+46 703 35 84 49

Maria Dahllöf Tullberg
Head of IR, Communications & ESG
maria.tullberg@vimian.com
+46 736 26 88 86

Vimian Group AB (publ)
Reg. no. 559234-8923
Riddargatan 19
114 57 Stockholm
Sweden
www.vimian.com

vimian™